The clinical research director of the UCSF Multiple Sclerosis Center discussed findings from the end-of-study analysis assessing inebilizumab which revealed a significant reduction in attack rates among patients with NMOSD over time. [WATCH TIME: 3 minutes]
An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.
The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]
The professor of neurology and executive vice chancellor and provost at the University of California, San Francisco detailed the connection between the gut microbiome and epilepsy.
Gene therapy has generated excitement as a treatment or even a potential cure for inherited diseases. Among them: Duchenne muscular dystrophy.
The professor of neurology at Washington University in St. Louis, and the president of the American Epilepsy Society, shared his perspective on John Hughlings Jackson’s observations of epilepsy in the brain and how it can inform modern practice. [WATCH TIME: 5 minutes]
The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]
Third year neurology resident Mona Al Banna, MB BCh BAO, MSc(Res) recounts her first major medical conference experience and provides guidance on how to make the most of your attendance, especially as a resident or fellow.
The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]
Many patients with neurologic conditions such as multiple sclerosis are faced with gait and stability issues due to their disease, but Splichal and Naboso Technology seek to address these issues via mechanoreceptor stimulation.
The director of the Multiple Sclerosis Program at UCLA discussed the need to consider HRT among women with MS going through menopause, and how HRT can improve its negative effects. [WATCH TIME: 4 minutes]
The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.
The director of the Center of Neurogenetics at Weill Cornell Medicine spoke about the wealth of improvements that have really turned this area of medicine into a much more hopeful one.
The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
The associate chief of the MS division and professor of neurology at Penn Medicine described the ongoing relationship between artificial intelligence and neurologists, and how it may evolve in the future.
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]
The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.
Experts on spasticity provide advice for practicing clinicians to optimize patient outcomes.
The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.
The research fellow at the University of Exeter spoke about the findings from her observational study which showed that living a favorable lifestyle could offset the risk for dementia, even if that risk is genetically linked. 


Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.